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BACKGROUND: The preventive effect of low-dose aspirin
in cardiovascular disease is generally attributed to its
antiplatelet action caused by differential inhibition of
platelet cyclooxygenase-1. However, there is evidence
that  aspirin  also  affects  release  of  inflammatory
cytokines, including tumor necrosis factor-a (TNF-a ).
It is not known whether this is caused by direct action
on  the  cytokine  pathway  or  indirectly  through
cyclooxygenase  inhibition  and  altered  prostanoid
synthesis, or both.
Methods:  We  assessed  the  capacity  of  lipopolysac-
charide-activated leukocytes in whole blood cultures
of eight healthy subjects following a single oral dose
of  80 mg  aspirin  to  release  TNF-a ,  prostanoid  E2
(PGE2) and prostanoid I2 (PGI2), and thromboxane A2
(TXA2). TNF-a and prostanoids were determined by
enzyme-linked immunoassays.
Results:  In  seven  subjects,  TNF-a release  in  blood
cultures  decreased 24h after  intake  of aspirin.  The
effect of aspirin on prostanoid release was assessed in
three individuals: PGE2 increased in all subjects, PGI2
increased  in  two  and  remained  unchanged in  one,
and TXA2 was reduced in two and unchanged in one
individual. The presence of DFU, a specific inhibitor
of cyclooxygenase 2, did not affect the reduction of
TNF-a release  by  aspirin,  but  abolished  prostanoid
production in all three individuals.
Conclusion:  The  capacity  of  activated  leukocytes  to
release  TNF-a is  reduced  by  ingestion  of  low-dose
aspirin,  independent  of  changes  in  prostanoid
biosynthesis.
Key  words:  Low-dose  aspirin,  Tumor  necrosis  factor-a ,
Cyclooxygenase inhibition, Prostanoids
Introduction
The demonstrated benefits of low-dose aspirin in the
prevention  of  cardiovascular  disease  are  generally
explained  by  differential  inhibition  of  the  constitu-
tive  cyclooxygenase  enzyme  cyclooxygenase-1
(COX-1) in platelets, resulting in a reduced synthesis
of vasoconstrictive and platelet aggregation stimulat-
ing thromboxane A2 (TXA2).1,2 The same mechanism
is  thought  to  be  involved  in  the  still  disputed
prevention of pre-eclampsia and fetal growth retarda-
tion  (FGR)  by  low-dose  aspirin.3–5 Recent  studies
have focused on the importance of release of inflam-
matory  cytokines,  such  as  tumor  necrosis  factor-a
(TNF-a ),  in  the  pathophysiology  of  these  vascular
events.6–9 It  is  known  that  the  biosynthesis  and
release of inflammatory  cytokines by  activated leu-
kocytes are affected by prostanoid E2 (PGE2), prosta-
noid  I2 (PGI2)  and TXA2,10,11 produced  simultane-
ously  in  activated  mononuclear  cells  through
induced cyclooxygenase COX-2. Results of two stud-
ies indicate that in  vivo exposure  to aspirin  alters
the  release  of  TNF-a by  peripheral  blood  mono-
nuclear cells,12,13 but it is not clear whether this is a
direct  effect  caused  by  inhibition  of  the  cytokine
pathway, an indirect effect due to inhibition of COX-
1  and/or  COX-2,  or  whether both  mechanisms are
involved.
Our study was designed to assess the effect of ‘in
vivo’ exposure to a single low dose of aspirin on the
release of TNF-a , PGE2, PGI2 and TXA2 by lipopoly-
saccharide (LPS)-activated leukocytes in whole blood
culture,  and  to  investigate  their  interaction  under
the  influence  of  aspirin.  In  some  of  our  experi-
ments, the effect of prostanoids TNF-a synthesis was
eliminated by blocking the synthesis of PGE2, PGI2
and  TXA2 in  LPS-activated  monocytes  with  DFU
(5,59 -dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)
phenyl-2(5H)-furanone), a specific inhibitor of indu-
cible COX-2.14
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Materials
Aspirin  (acetylsalicylic  acid,  non-coated, 80mg  tab-
lets) was obtained from Pharmachemie B.V. (Haarlem,
The Netherlands). DFU was kindly provided by Merck
Frosst (Quebec, Canada) through the courtesy of Dr
A.  W.  Ford-Hutchinson.  TNF-a was  obtained  from
Knoll  (Ludwigshafen,  Germany).  Mouse  anti-human
TNF-a monoclonal antibody (mAb1) and biotinylated
mouse  anti-human  TNF-a monoclonal  antibody
(mAb11)  for  enzyme-linked  immunosorbent  assay
(ELISA)  determinations were  purchased  from  Phar-
Mingen (San Diego, CA, USA). Cell culture medium
RPMI  and  supplements  were  obtained  from  Life
Technologies B.V. (Breda, The Netherlands). Streptavi-
din–horseradish  peroxide  conjugate  was  obtained
from the Central Laboratory of the Netherlands Red
Cross  Blood  Transfusion  Service  (Amsterdam,  The
Netherlands). LPS Escherichia coli 0111  B4, bovine
serum albumin (BSA), 3,39 ,5,59 -tetramethylbenzidine
(TMB) and Tween 20 (polyoxyethylenesorbitan mono-
laureate) were purchased from Sigma (St. Louis, MO,
USA). All other chemicals were from  Merck (Darm-
stadt, Germany).
Study subjects
Nine  healthy  female,  non-pregnant  volunteers  aged
24–35  years  participated  in  the  study.  Informed
consent was obtained from all subjects. Participants
used oral contraceptives but no other drugs during at
least 2 weeks before and during the experiments.
Sampling
Venous blood was obtained from all subjects imme-
diately before (day 1, 8.00 a.m.) and 24h after oral
intake of 80mg aspirin (day 2). One subject ingested
80mg  aspirin  for  15  consecutive  days  and  was
sampled on days 1, 2, 9, 13 and 16. Blood samples
were drawn into endotoxin-free vacutainers (Becton-
Dickinson) with ethylenediamine tetraacetic acid as
anticoagulant  and  processed  immediately  after
sampling.
Whole blood cultures
Seven  hundred  and  fifty  microliters  of  blood  were
diluted 1:10  with RPMI 1640  culture  medium with
25 mM  Hepes,  supplemented  with  100U/ml  pen-
icillin,  100 m g/ml  streptomycin,  4 mM  L-glutamine
and 10% fetal calf serum, and then incubated in the
presence of LPS E. coli O111 B4 (20 m g/ml full blood,
dissolved in phosphate-buffered saline (PBS) (pH 7.4))
for 0–48h at 37°C and 5% CO2. Blood cultures were
sampled at 0, 12, 24 and 48h, samples centrifuged for
10min at 1500 ´ g and culture supernatants kept at
–80°C until analysis.
Inhibition of COX-2 in whole blood cultures
Seven  hundred  and  fifty  microliters  of  blood  were
diluted with RPMI 1640  culture  medium as already
described  and  incubated  with  4 m l  DFU  solution
(5 m M  in  dimethylsulfoxide  (DMSO))  for  15min  at
37°C and 5% CO2. LPS was added and blood cultures
were processed as already described.
Determination of TNF-a
TNF-a in blood culture supernatants was determined
by  an  enzyme-linked  immunoassay  (PharMingen
ELISA)  using  one  capturing  monoclonal  antibody.
Briefly,  96-well  microtiter plates  were  coated over-
night  at  4°C  withmAb1  (25ng/well)  in  0.1M
NaHCO3 (pH  8.2).  The  plates  were  washed  with
washing buffer PBS (pH 7.4)/Tween 20 (PBS/Tween;
1000:1)  and  incubated  for  2h  with  a  3%  (w/v)
solution of BSA in  PBS (200 m l/well). After washing
with  PBS/Tween,  TNF-a standards  and  samples,
diluted  in  complete  RPMI  1640  culture  medium,
were  applied  and  incubated  overnight  at  4°C. The
microtiter  plates  were  washed  again  with  PBS/
Tween and incubated with biotinylated monoclonal
anti-human  TNF-a antibodymAb-11  (50ng/well,  in
complete RPMI 1640 culture medium) for 45min at
room  temperature. After  washing  with  PBS/Tween,
the plates were further incubated with peroxidase-
labeled  streptavidin  (25ng/well  in  Tris–HCl  buffer
(pH 8.0) with 0.1% gelatine, 0.1% caseine and 0.02%
Tween).  After  incubation  for  30min  at  room  tem-
perature and washing with PBS/Tween, 100 m l TMB
chromogene  solution  (100 m g TMB/ml  sodium  ace-
tate solution (pH  5.5)  with 1 m l of  3% H2O2) were
added,  incubated  in  the  dark  for  30min  at  room
temperature and the substrate reaction stopped with
1M  H2SO4 (100m l/well). The  absorbance  per  well
was  measured  at  450nm  with  a  Medgenix  EASIA
reader,  and TNF-a concentrations in  samples calcu-
lated using the TNF-a standard calibration line. Intra-
assay and interassay coefficients of variation were 10
and  15%,  respectively,  and  the  detection limit  was
10pg/ml.  Results  are  expressed  as  nanograms  of
TNF-a per milliliter  of blood or calculated as nano-
grams of TNF-a per 105 monocytes in the longitudi-
nal experiment with subject 9. In subjects 5–7, TNF-
a concentrations in  culture  supernatants were also
determined  with  a  commercially  available  enzyme
amplified sensitivity immunoassay (EASIA; BioSource
Europe  S.A.,  Fleurus,  Belgium)  with  three  mono-
clonal antibodies detecting different epitopes on the
TNF-a molecule.  Intra-assay  and  interassay  coeffi-
cients of variation were 6 and 10%, respectively, and
the detection limit was 3pg/ml.
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For  purification  of  prostanoids  in  blood  culture
supernatants,  a  Sep-Pak  C18 cartridge  (Waters,  Mil-
ford, MA, USA) was prewashed with 10ml absolute
ethanol,  10ml  distilled  water,  and  2ml  air.  One
milliliter  of culture  supernatant was applied to the
cartridge and the cartridge washed with 2ml distilled
water,  and  the  prostanoids were  eluated  with 1ml
absolute ethanol, followed by 2ml air. The eluate was
dried  at  40°C  under  vacuum  in  a  Speed-Vacuum-
Concentrator, dissolved in assay buffer according to
the instructions of the manufacturer, and analyzed.
TXA2 with a half-life of approximately 30sec under
physiological conditions was measured as its stable
metabolite TXB2,  and  PGI2 as  its  stable  metabolite
6-keto-prostaglandin  F1a .  All  determinations  were
performed  using  commercially  available  enzyme-
linked immunoassays (EIA system; Amersham Pharma-
cia Biotech UK, Little Chalfont, UK) with the follow-
ing intra-assay and interassay coefficients of variation
and  detection  limits,  respectively:  for  PGE2,  10%,
10%, and 40pg/ml; for PGI2, 7%, 15%, and 3pg/ml;
for TXB2, 14%, 10%, and 3.6pg/ml. Cross-reactivities
with related substances were below 0.1%. The results
were  calculated  as  nanograms  of  prostanoid  per
milliliter of blood or per 105 monocytes.
Results
Change in TNF-a release in LPS-stimulated
whole blood cultures after aspirin ingestion
In  seven  of  the  eight  tested  healthy  women,  oral
ingestion of 80mg aspirin induced a decrease of TNF-
a release in LPS-stimulated blood cultures 24h after
aspirin intake when compared with values obtained
before aspirin ingestion; in one subject, TNF-a secre-
tion was unaffected by aspirin intake. Figure 1 shows
a  marked  individual  variation  in  time  course  and
magnitude  of  the  aspirin-induced  change  in TNF-a
release,  which  was  observed  in  five  out  of  seven
blood cultures already after 12h of cultivation, and in
seven cases after 24 and 48h. The absolute values for
TNF-a as determined for subjects 1–8 are summarized
in Table 1.
In subjects 5, 6 and 7, in whom TNF-a determina-
tions were repeated with the enzyme-amplified sensi-
tivity  immunoassay,  absolute TNF-a values  differed
between  the  two  immunoassays,  but  the  trend  in
aspirin-induced changes of TNF-a release was identi-
cal in all three subjects.
Effect of COX-2 inhibition on changes in TNF-a
release in LPS-stimulated blood cultures after
aspirin ingestion
TNF-a release in LPS-stimulated whole blood cultures
was investigated in the presence of the specific COX-
TNF-a and prostanoids in blood culture after aspirin
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Table 1. Tumor necrosis factor-a (TNF-a ) concentrations in blood culture supernatants after 12, 24 and 48h of cultivation before
and 24h after intake of 80mg aspirin in eight healthy women
Subject number TNF-a (ng/ml) after 12h TNF-a (ng/ml) after 24h TNF-a (ng/ml) after 48h
1 20.2, 16.7 16.7, 11.5 10.8, 6.7
2 61.1, 44.1 57.1, 29.7 30.1, 17.6
3 42.6, 39.3 38.3, 29.5 18.1, 5.8
4 65.3, 28.6 37.8, 12.7 11.1, 1.4
5 53.7, 51.2 43.6, 32.8 24.0, 12.4
6 99.7, 84.9 72.5, 53.9 23.1, 15.6
7 111.1, 73.4 72.7, 44.6 22.1, 13.6
8 30.6, 40.6 18.0, 18.5 5.1, 5.1
Data presented as before aspirin intake, after aspirin intake. TNF-a concentrations in lipopolysaccharide-stimulated blood cultures of subjects 1–8
were determined by an enzyme-linked immunoassay (Pharmingen) and are calculated as nanograms per milliliter of blood. In all subjects, TNF-a
concentrations at 0h were below the detection limit of the assay.
FIG. 1. Changes in tumor necrosis factor-a (TNF-a ) release in
lipopolysaccharide (LPS)-stimulated blood cultures of seven
healthy women 24h after ingestion of 80mg aspirin. Venous
blood, sampled immediately before and 24h after oral intake
of  80mg  aspirin,  was  diluted  1:10 in complete  RPMI and
cultivated for 48h in the presence of Escherichia coli O111 B4
LPS. Blood cultures were sampled at 0, 12, 24 and 48h, and
supernatants  analysed  by  a  screening  line  immunoassay
using a single monoclonal antibody for TNF-a detection. The
different lines (1–7) represent TNF-a release 24h after aspirin
ingestion as a percentage of values obtained before aspirin
intake in seven women (subjects 1–7).2 inhibitor, DFU, in subjects 5, 6 and 7 before and
after intake of 80mg aspirin. The maximal inhibitory
dose  of  DFU  was  determined  in  preliminary  tests
(data not shown) and applied in a 10  times higher
concentration  in  the  experiments.  Figure  2  shows
that the presence of DFU during blood cultivation had
no  influence  on  the  reduction  of TNF-a release in
blood cultures 24h after aspirin intake.
Effect of aspirin intake on release of PGE2, PGI2
and TXA2 in LPS-stimulated whole blood
cultures
The  effect  of  a  single  dose  of  80mg  aspirin  on
prostanoid  release  in  LPS-stimulated  whole  blood
cultures  was  investigated  in  the  absence  and  pres-
ence of DFU in subjects 5, 6 and 7. All three subjects
showed a  marked  increase in  PGE2 release already
after 24h of cultivation time, whereas this increase
rose with prolonged cultivation. The effect of aspirin
on release of PGI2 was less pronounced and differed
individually; PGI2 secretion showed a slight increase
in subjects 5 and 6, and remained almost unchanged
in subject 7. TXA2 release was almost unchanged in
subject 5, and fell slightly in subjects 6 and 7. In all
three subjects, cultivation of blood in the presence
of  DFU  reduced  prostanoid  production  to  a  base
level, and no effect of aspirin could be detected. In
view of pronounced inter-individual differences, the
results  are  presented  for  each  case  separately  in
Figure 3.
Effect of daily ingestion of 80mg aspirin on
release of TNF-a and prostanoids in
LPS-stimulated whole blood cultures
In an additional experiment in one woman, designed
to look into the consequences of continuous intake
of  80mg  aspirin  for  the  capacity  of  leukocytes  to
secrete  TNF-a and  prostanoids  in  LPS-stimulated
blood  cultures,  subject  9  ingested  aspirin  for  15
consecutive days. Daily aspirin intake and preceding
blood  sampling  were  scheduled  for  8.00  a.m.  in
order  to  avoid  a  circadian  influence  on  cytokine
secretion.15 Differential  white  blood  cell  counts
(Cysmex NE 8000) performed for each blood sample
showed  a  variation  of  leukocyte  and  leukocyte
subtype  numbers  during  the  course  of  the  experi-
ment. Leukocytes varied between 4.9 ´ 106 and 6.1
´ 106/ml, and monocytes between 3.7 ´ 105 and 6.8
´ 105/ml. With the monocyte as the main source for
release of TNF-a and prostanoids after LPS  stimula-
tion, analytical data were calculated per 105 mono-
cytes  and  compared  as  values  per  105 monocytes.
TNF-a determinations  were  performed  with  the
enzyme  amplified  sensitivity  immunoassay  (Bio-
Source). Figure  4 shows the results of TNF-a deter-
minations during the experiment. Daily ingestion of
aspirin  reduced  the  release  of TNF-a in  blood  cul-
tures  after  12  days  to  a  level  of  48%  of  the  value
obtained before aspirin intake. In this subject, inges-
tion  of  aspirin  for  three  more  days  achieved  no
further reduction of TNF-a secretion. The presence
of DFU during blood cultivation did not change the
results  as  presented  in  Figure  4.  In  subject  9,  the
release of all three prostanoids was reduced already
after intake of one aspirin and reached a minimum
after ingestion of 12 aspirin tablets, with no further
reduction  after  intake  of  three  more  tablets.  The
presence  of  DFU  in  blood  cultures  abolished  the
release of prostanoids almost completely (Fig. 5).
Discussion
Preliminary experiments in unstimulated whole blood
cultures  of  healthy  individuals  showed  that TNF-a
release was low, and aspirin ingestion reduced TNF-a
levels  to  values  below  the  detection  level  of  the
immunoassays. For these reasons, TNF-a release from
leukocytes in blood cultures  was stimulated with a
maximal stimulating dose of E. coli LPS. The use of a
whole  blood  culture  model  has  advantages  when
compared  with  cultures  of  isolated  monocytes  or
macrophages. It permits interaction between differ-
ent leukocytes and between leukocytes and prosta-
noids  released during  cytokine biosynthesis,  and  it
avoids  depletion  or  enrichment  of  monocyte  sub-
populations  during  monocyte  isolation  or  uncon-
trolled  activation  of  monocytes  by  purification
procedures.16
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FIG.  2.  Effect  of  cyclooxygenase-2  (COX-2)  inhibition  on
tumor necrosis factor-a (TNF-a ) release in lipopolysacchar-
ide (LPS)-stimulated blood cultures of three healthy women
24h after ingestion of 80mg aspirin. For subjects 5, 6 and 7,
LPS-stimulated blood cultures before and 24h after aspirin
intake were prepared without and with the COX-2 inhibitor
DFU (10m M in dimethylsulfoxide). TNF-a in culture super-
natants was determined by a screening line immunoassay.
The change in TNF-a release by aspirin intake was calculated
as the percentage of values obtained before aspirin inges-
tion.  Solid  lines,  change  in  TNF-a release  without  DFU;
dashed lines, change in TNF-a release in the presence of
DFU.Although  the  female  volunteers  in  our  study
express the known inter-individual quantitative differ-
ences in LPS-induced TNF-a production,17,18 ingestion
of one low dose of aspirin resulted in a reduction of
TNF-a release  by  activated  leukocytes  in  seven  of
eight subjects. This indicates a fundamental effect of
aspirin intake on TNF-a biosynthesis. The observed
inter-individual  variability  in  aspirin-induced  reduc-
tion of TNF-a release, varying from 20 to 66% at 24h
of blood culture, may be explained by differences in
absorption, metabolism and clearance of the drug. It
is  questionable  whether the  observed reduction  in
TNF-a release in full blood cultures 24h after inges-
tion  of  80mg  aspirin  is  mediated  by  aspirin  itself.
TNF-a and prostanoids in blood culture after aspirin
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FIG. 3. The effect of ingestion of 80mg aspirin on the production of prostanoid E2 (PGE2), prostanoid I2 (PGI2) and thromboxane
A2 (TXA2)  in  lipopolysaccharide  (LPS)-stimulated  blood  cultures,  measured  in  the  absence  and  presence  of  the  cyclo-
oxygenase-2 inhibitor DFU. LPS-stimulated blood cultures of subjects 5, 6 and 7 were prepared without and with DFU (10m M
in dimethylsulfoxide) before and 24h after intake of 80mg aspirin. Prostanoids in culture supernatants were extracted by
absorption on C18-cartridges and eluation with absolute ethanol, and determined by immunoassays. Solid lines, prostanoid
values (ng/ml) before aspirin intake; dashed lines, prostanoid values (ng/ml) after aspirin intake.Aspirin has a half-life of 20–30min in the circulation
and  is  deacetylated  in  the  liver  to  salicylic  acid.
Salicylicate with a half-life of approximately 3h at the
usual therapeutic doses is cleared through the kidney
as a glycine or glucuronic acid conjugate or metabo-
lized to gentisic acid (2,5-dihydroxybenzoate).19 This
suggests that salicylic acid and metabolites rather than
acetylsalicylic  acid may  participate in  the observed
reduction of TNF-a release 24h after aspirin ingestion.
The  inhibitory  effect  of  aspirin  on  COX-2-induced
prostaglandin biosynthesis in activated mononuclear
cells is less pronounced than the blocking capacity of
aspirin  for  constitutive  COX-1,20 but  aspirin  and
salicylate have been shown to inhibit  PGE2 release
from LPS-stimulated monocytes in vitro,21 as well as
in vivo after oral ingestion of aspirin.12,13 In contrast
to these studies, our results show an increase of PGE2
secretion in all three tested subjects after a single low
dose of aspirin. The discrepancy in the effect on PGE2
release  could  depend  on  the  different  dosage  of
aspirin  and  salicylate  applied  in  other  studies,12,13
where doses of 300mg or more per day were used.
The increase of  PGI2 release after oral ingestion of
80mg aspirin in two of the three subjects in our study
was less pronounced than the effect on PGE2 release,
and  of  similar  magnitude  to  the  decrease in TXA2
secretion. Inhibition of COX-2 with the specific COX-
2 inhibitor DFU abolished prostanoid release almost
completely, which indicates that all three prostanoids
are products of LPS-induced COX-2 activity.
The three investigated prostanoids are known to
affect  the  biosynthesis  of TNF-a .10,11 The  effect  of
I. Beckmann et al.
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FIG. 4. The effect of a daily intake of 80mg aspirin on the
release  of  tumor  necrosis  factor-a (TNF-a )  from  lipopoly-
saccharide (LPS)-stimulated blood cultures from a healthy
woman. Subject 9 ingested 80mg aspirin for 15 consecutive
days. Blood was sampled immediately before aspirin intake
(day 1) and on days 2, 9, 13 and 16. An automatic differential
leukocyte  count  (Cysmex  NE  8000)  was  performed  in  all
blood  samples.  LPS-stimulated  blood  cultures  were  pre-
pared,  and  TNF-a concentrations  in  blood  culture  super-
natants  measured  by  a  Biosource  enzyme  immunoassay
using three monoclonal antibodies for TNF-a detection and
calculated as nanograms per 10
5 monocytes.
FIG. 5. The effect of a daily intake of 80mg aspirin on the
release of prostanoids from lipopolysaccharide (LPS)-stim-
ulated  blood  cultures  from  a  healthy  woman.  Subject  9
ingested 80mg aspirin for 15 consecutive days. Blood was
sampled  immediately  before  (day  1)  and  after  aspirin
intake  on  days  2,  9,  13  and  16.  Monocytes  in  blood
samples  were determined by  differential leukocyte  count-
ing with a Cysmex NE 8000. LPS-stimulated blood cultures
without  and  with  the  cyclooxygenase-2  inhibitor  DFU
(10m M  in  dimethylsulfoxide)  were  prepared,  prostanoids
extracted  from  blood  culture  supernatants  by  absorption
on  C18 cartridges  and  eluation  with  absolute  ethanol,
and  determined by immunoassays.  Values  for  (A)  prosta-
noid E2 (PGE2), (B) prostanoid I2 (PGI2), and (C) thrombox-
ane  A2 (TXA2)  were  calculated  as  nanograms  per  10
5
monocytes.  Concentrations  of  prostanoids  in  blood  cul-
tures  with  DFU  were  all  below  the  indicated  reference
lines.PGE2 on TNF-a biosynthesis in activated monocytes is
dose dependent: low  concentrations of  PGE2 stim-
ulate,  and  higher concentrations inhibit TNF-a pro-
duction.22 The  stable  PGI2 analogs  iloprost  and
cicaprost suppress TNF-a synthesis in LPS-stimulated
peripheral  blood  mononuclear  cells.23 It  has  been
shown that TXA2 in activated monocytes functions as
a paracrine or autocrine facilitator of TNF-a synthesis,
which is at least in part determined by the balance
between  PGE2 and TXA2 concentrations.11 Aspirin-
induced changes in prostanoid concentrations could
therefore  affect TNF-a release  in  stimulated  blood
cultures. Our results show that inhibition of prosta-
noid biosynthesis by the specific COX-2 inhibitor DFU
had no influence on the aspirin-induced reduction in
TNF-a release, indicating that it is induced through a
pathway independent of prostanoid synthesis.
The production of TNF-a in LPS-stimulated mono-
cytes  and  macrophages is  a  multistep  process  that
requires  the  liberation  of  the  nuclear  transcription
factor k B (NF-k B)24 from an inhibitory protein, Ik B.
Release of  NF-k B  is achieved through phosphoryla-
tion  and  subsequent  degradation  of  Ik B  by  two
cellular  kinases,  IKK-a and  IKK-b .25 Aspirin  and
salicylate  were  shown  to  inhibit  specifically  the
activity of IKK-b , thus preventing the activation of NF-
k B  and  the  NF-k B-induced  transcription  of  genes
responsible for TNF-a biosynthesis.21,26 It should be
noted that inhibition of IKK-b activity by aspirin or
salicylic acid in both ‘in vitro’ studies was achieved
with concentrations equivalent to anti-inflammatory
doses  in  vivo.  Our  results,  showing  an  aspirin-
induced  decrease in TNF-a release  from  LPS-stimu-
lated full blood, are in agreement with these funda-
mental  observations,  but  it  remains  questionable
whether  plasma  levels  achieved  after  ingestion  of
80mg  are  sufficient  to  inhibit  IKK-b activity.  Our
results are contrary to the results of two studies,12,13
in  which  oral  ingestion  of  aspirin  increased TNF-a
secretion from LPS-stimulated monocytes. It is possi-
ble that the higher doses of aspirin (300 and 325mg/
day) that were used in these studies induce responses
in  mononuclear  cells  that  are  different  from  those
obtained with low-dose aspirin. The influence of LPS
concentrations during stimulation of isolated mono-
cytes  or  whole  blood  cultures  on  aspirin-induced
changes of TNF-a release was recently discussed by
Osnes et al.27 Stimulation with low concentrations of
LPS  as  used  in  the  aforementioned  studies  could
activate  signalling  pathways  different  from  those
activated by high LPS concentrations that were used
in  our  study  and  by  Osnes  et  al. in  earlier  experi-
ments,21 where aspirin reduced TNF-a release from
LPS-stimulated monocytes.
We  cannot  exclude  the  possibility  that  eicosa-
noids  like  15-(R)-hydroxyeicosatetraenoic  acid
(15-(R)-HETE),  produced by aspirin-acetylated COX-
228 and  known  to  reduce  TNF-a secretion  by
human  monocytes,29 and  lipoxygenase-mediated
lipoxins participate in the observed effect of aspirin
ingestion on TNF-a release. However, the induction
of  COX-2  by  LPS  in  our  experiments  was  initiated
24h after oral low-dose aspirin intake. By this time,
aspirin  should  be  completely  metabolized.30,31
Acetylated COX-1 seems to be unable to synthesize
HETE-like products.32
In the single  experiment with multiple  intake of
low-dose  aspirin,  the  inhibition  of  TNF-a release
became stable after 12 days; ingestion of three more
aspirin  did  not  further  reduce TNF-a release. The
permanent  reduction  of  TNF-a secretion  in  this
experiment after continuous low-dose aspirin inges-
tion might be involved in the beneficial effects of the
drug that were observed in pathological conditions
like pre-eclampsia and FGR, where increased TNF-a
release was detected. This requires confirmation by
further experiments.
To  our  knowledge  this  is  the  first  report  of  the
effect  of  low-dose aspirin  after  single  and  multiple
intake on the release of TNF-a , PGE2, PGI2 and TXA2
in LPS-stimulated full blood cultures. Further studies
with more subjects are needed to confirm and extend
these first results. The question of whether salicylate
and gentisic acid as metabolites of aspirin and/or lipid
products of acetylated COX isoenzymes participate in
the described effects on peripheral mononuclear cells
remains to be answered.
TNF-a and prostanoids in blood culture after aspirin
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